Literature DB >> 16874718

The discovery of diabetic nephropathy: from small print to centre stage.

J S Cameron1.   

Abstract

Until the early nineteenth century, diabetes mellitus was regarded as a disease of the kidney, in which there was an increase in the volume of urine and a wasting of the flesh. With the identification of glucose in blood and urine in the late eighteenth century, first it was re-framed as a disease of assimilation and only then became a metabolic disorder. Whilst these changing concepts were debated, it was noted in parallel that diabetics might show coagulable urine containing albumin, even before Bright and others had established this as a sign of kidney disease. Wilhelm Griesinger (1817-1868) was perhaps the first to suggest in 1859 that the diabetes might be causing the Bright's disease, with the latter as a 'complication'. During the next half-century the observation that as albuminuria appeared and increased, so glycosuria improved or might remit, with a parallel or subsequent evolution into uraemia. Glomerulosclerosis and arteriolosclerosis were described in occasional patients during the same period, but text-books of pathology ignored these observations. Thus it was only when diabetics began to survive longer using insulin treatment in the early 1920s that a diabetic nephropathy became widely recognized. After a few isolated descriptions which were ignored, the now famous paper of Paul Kimmelstiel and Clifford Wilson appeared in 1935 detailing nodular renal lesions in just 8 maturity-onset (48-68 year old) diabetics. They barely noted the association with diabetes however, and it was Arthur Allen in 1941 who clarified the association in 105 patients with diabetes, again all aged over 40. Despite the age of the patients in these early studies, diabetic nephropathy became thought of as a disease of young diabetics as a cohort of survivors of juvenile diabetes passed 15 years or more of disease and more than half developed nephropathy. In the 1950s the technique of renal biopsy was rapidly applied to the study of diabetics, and the early lesions defined using electron microscopy as well as optical methods. Then the role of diabetic nephropathy as a cause of renal failure changed: to begin with numbers of young insulin-requiring diabetics were small and infrequently referred for dialysis treatment or transplantation. Then in the 1970s and 1980s the proportion of such juvenile-onset diabetics developing renal failure gradually fell, but at the same time much larger numbers of older diabetics survived their vascular disease and required treatment for renal failure. World-wide, today diabetes accounts for 20-50% of patients entering established renal failure programs, and absolute numbers increase as greater longevity and western-style living has promoted an 'epidemic' of diabetes at all ages.

Entities:  

Mesh:

Year:  2006        PMID: 16874718

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  13 in total

1.  Network-centric Analysis of Genetic Predisposition in Diabetic Nephropathy.

Authors:  A Ntemka; F Iliadis; Na Papanikolaou; D Grekas
Journal:  Hippokratia       Date:  2011-07       Impact factor: 0.471

2.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Authors:  Radica Z Alicic; Michele T Rooney; Katherine R Tuttle
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 8.237

3.  Genome-wide association study of brain arteriolosclerosis.

Authors:  Lincoln Mp Shade; Yuriko Katsumata; Timothy J Hohman; Kwangsik Nho; Andrew J Saykin; Shubhabrata Mukherjee; Kevin L Boehme; John Sk Kauwe; Lindsay A Farrer; Gerard D Schellenberg; Jonathan L Haines; Richard P Mayeux; Julie A Schneider; Peter T Nelson; David W Fardo
Journal:  J Cereb Blood Flow Metab       Date:  2022-02-14       Impact factor: 6.960

4.  The effects of synthetic orally administrated insulin nanoparticles in comparison to injectable insulin on the renal function markers of type 1- diabetic rats.

Authors:  Nejat Kheiripour; Behnam Alipoor; Akram Ranjbar; Yasin Pourfarjam; Farzaneh Kazemi Najafabadi; Narges Dehkhodaei; Masoumeh Farhadiannezhad; Hassan Ghasemi
Journal:  Iran J Basic Med Sci       Date:  2020-06       Impact factor: 2.699

5.  Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy.

Authors:  Anne Julie Overgaard; Henning Gram Hansen; Maria Lajer; Lykke Pedersen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Journal:  Proteome Sci       Date:  2010-02-03       Impact factor: 2.480

6.  Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients.

Authors:  Anne Julie Overgaard; Tine E Thingholm; Martin R Larsen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Journal:  Clin Proteomics       Date:  2010-09-10       Impact factor: 3.988

Review 7.  Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease.

Authors:  Giorgina B Piccoli; Giorgio Grassi; Gianfranca Cabiddu; Marta Nazha; Simona Roggero; Irene Capizzi; Agostino De Pascale; Adriano M Priola; Cristina Di Vico; Stefania Maxia; Valentina Loi; Anna M Asunis; Antonello Pani; Andrea Veltri
Journal:  Rev Diabet Stud       Date:  2015-08-10

8.  Determinants of intravascular resistance in Indian diabetic nephropathy patients: a hospital-based study.

Authors:  Anubhav Thukral; Manish Mishra; Vaibhava Srivastava; Hemant Kumar; Amit Nandan Dhar Dwivedi; Ram Chandra Shukla; Kamlakar Tripathi
Journal:  Int J Vasc Med       Date:  2011-06-12

Review 9.  Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review.

Authors:  Davida Kruger; Virginia Valentine
Journal:  Diabetes Ther       Date:  2020-05-13       Impact factor: 2.945

Review 10.  The Multi-Therapeutic Role of MSCs in Diabetic Nephropathy.

Authors:  Yi Wang; Su-Kang Shan; Bei Guo; Fuxingzi Li; Ming-Hui Zheng; Li-Min Lei; Qiu-Shuang Xu; Muhammad Hasnain Ehsan Ullah; Feng Xu; Xiao Lin; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.